Stable efficacy and safety after switching from intravenous to subcutaneous tocilizumab in a cohort of 200 patients in real life conditions

Joint Bone Spine. 2022 Jul;89(4):105347. doi: 10.1016/j.jbspin.2022.105347. Epub 2022 Jan 20.
No abstract available

Keywords: Antirheumatic agents; Drug switch; Drug therapy; Rheumatoid arthritis; Tocilizumab.

Publication types

  • Letter

MeSH terms

  • Administration, Intravenous
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antirheumatic Agents* / adverse effects
  • Cohort Studies
  • Drug Therapy, Combination
  • Humans
  • Injections, Subcutaneous
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • tocilizumab